[pubmed] Rituximab in Refractory Myasthenia Gravis: Experience in a Single Healthcare Center in Mexico
Posté : 17 mars 2021 11:00
Cureus. 2021 Feb 8;13(2):e13226. doi: 10.7759/cureus.13226.
ABSTRACT
BACKGROUND: Ten to fifteen percent of patients with myasthenia gravis (MG) have treatment-refractory disease. In short series and case reports, rituximab has proven to be effective in refractory MG.
METHODS: A retrospective, longitudinal study was conducted. Recruitment was performed in an MG cohort from a single third-level healthcare center in Mexico. The selection included refractory MG patients that were treated with rituximab. Response after rituximab therapy was assessed with MG composite score (MGCS) and prednisone dose reduction at 6, 12, and 18 months after initiation. Wilcoxon signed-rank test was used to evaluate differences between related groups for non-continual variables. P
Source: https://pubmed.ncbi.nlm.nih.gov/3372817 ... 8&v=2.14.3